Prefusion RSV F proteins and their use

US11981707B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Peter Kwong · Washington, US
• Barney Graham · Rockville, US
• Jason McLellan · Austin, US
• Jeffrey Boyington · Clarksburg, US
• Lei Chen · Singapore, SG
• Man Chen · Shanghai, CN
• Gwo-Yu Chuang · Rockville, US
• Ivelin Georgiev · Nashville, US
• Jason Gorman · Washington, US
• Michael Gordon Joyce · Washington, US
• Masaru Kanekiyo · Bethesda, US
• Gilad Ofek · Gaithersburg, US
• Marie Pancera · Seattle, US
• Mallika Sastry · Rockville, US
• Cinque Soto · Rockville, US
• Sanjay Srivatsan · Lilburn, US
• Guillaume Stewart-Jones · Cambridge, US
• Yongping Yang · Potomac, US
• Baoshan Zhang · Bethesda, US
• Tongqing Zhou · Boyds, US

Key dates

• Filing date: Sep 11, 2023
• Grant date: May 14, 2024
• Expiry date: Sep 11, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.